How should an outpatient transition be managed for a patient discharged on insulin glargine (basal insulin)?

Outpatient Transition for Patients Discharged on Insulin Glargine

Discharge patients on insulin glargine at the doses they received in the hospital, with follow-up timing and regimen adjustments determined by their HbA1c level and glycemic control during hospitalization.

Discharge Insulin Dosing Strategy

The transition approach depends critically on the patient's diabetes type, pre-admission treatment, and glycemic control as measured by HbA1c 1:

For Type 1 Diabetes Patients

• Continue basal-bolus regimen: Patients must leave on both basal insulin (glargine) AND rapid-acting prandial insulin at the doses used during hospitalization 1
• The basal insulin alone is insufficient for Type 1 diabetes management 2

For Type 2 Diabetes Patients Previously on Insulin

HbA1c-Based Discharge Algorithm 1, 3:

• HbA1c < 8%: Resume pre-admission treatment at hospital doses; follow-up with primary care physician within 1-2 weeks 1

• HbA1c 8-9%:

  • If previously on oral agents + insulin: Resume oral agents (if no contraindications) and continue glargine at hospital dose
  • Discontinue rapid-acting insulin gradually as oral agents resume effect
  • Schedule endocrinology consultation for therapy intensification 1

• HbA1c > 9% OR persistent hyperglycemia (>200 mg/dL or 11 mmol/L):

  • Continue full basal-bolus regimen at 80% of inpatient total daily dose 3
  • Require endocrinology consultation before discharge, potentially for specialized diabetes service admission 1

For Type 2 Diabetes Patients Previously on Oral Agents Only

HbA1c-Based Approach 3:

• HbA1c < 7%: May resume pre-admission oral agents only; insulin may not be needed long-term

• HbA1c 7-9%: Discharge on pre-admission oral agents PLUS glargine at 50% of hospital total daily insulin dose 3

• HbA1c > 9%: Continue basal-bolus regimen; endocrinology consultation required 1

Critical Discharge Components

Medication Reconciliation 4, 5

• Verify insulin formulation: Confirm patients understand they are receiving insulin glargine 100 units/mL (Lantus), not other insulin products 5
• Timing: Administer once daily at the SAME TIME each day 5
• Prescriptions filled before discharge: Ensure patients have insulin and supplies in hand, not just prescriptions 4, 6

Patient Education - "Survival Skills" 1, 7

Must include:

• Recognition and treatment of hypoglycemia and hyperglycemia
• Proper insulin injection technique and site rotation 5
• Self-monitoring of blood glucose (frequency: before meals and bedtime minimum)
• Sick day management rules
• When to contact healthcare providers
• Understanding that insulin glargine should NEVER be diluted, mixed with other insulins, or given intravenously 5

Follow-Up Scheduling 4, 8, 7

Timing based on glycemic control 1, 4:

• Well-controlled (HbA1c < 8%): Primary care follow-up within 1 month
• Moderate control (HbA1c 8-9%): Endocrinology consultation within 2-4 weeks
• Poor control (HbA1c > 9% or unstable glucose): Follow-up within 1-2 weeks, potentially with diabetes educator 4, 8

Schedule appointments BEFORE discharge to increase attendance rates 4

Special Considerations

Transitioning from IV Insulin

If patient was on IV insulin infusion 1:

• Basal insulin dose: 50% of total 24-hour IV insulin requirement, given as single evening dose
• Prandial insulin: Remaining 50% divided equally before three meals (approximately 1/6 of 24-hour IV dose per meal)
• Administer first subcutaneous dose 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia

Hypoglycemia Risk Mitigation 5

High-risk populations requiring dose reduction:

• Age ≥70 years: Start at 0.2-0.3 units/kg 2
• Renal impairment (GFR <60 mL/min): Reduce doses, increase monitoring 2, 5
• Hepatic impairment: Increased hypoglycemia risk 5
• Patients with reduced hypoglycemia awareness 5

The long-acting effect of glargine may delay recovery from hypoglycemia 5

Medication Access Barriers 6, 9

• 21% of patients experience difficulty obtaining insulin and supplies post-discharge 9
• Provide prescriptions for: insulin, syringes/pens, blood glucose meter, test strips, lancets
• Consider cost: insulin glargine biosimilars may improve affordability 7
• Arrange home health nursing if needed for injection assistance 1

Communication with Outpatient Providers 4, 7

Discharge summary must include:

• Cause of hyperglycemia (stress vs. known diabetes vs. new diagnosis)
• Hospital glucose control and insulin requirements
• Discharge medication regimen with specific doses
• HbA1c value
• Recommended follow-up plan

Common Pitfalls to Avoid

1. Never discharge on sliding-scale insulin alone - this reactive approach leads to poor control and 3-fold increased hyperglycemia risk 2

2. Do not abruptly stop hospital insulin without transition plan - leads to dangerous hyperglycemia 2

3. Avoid medication errors: Patients must verify insulin type before each injection; glargine is easily confused with other insulins 5

4. Do not resume metformin without checking renal function (requires GFR >60 mL/min) 1

5. Glucocorticoid adjustments: If patient is on steroids being tapered, provide specific insulin adjustment instructions as steroid dose changes 9

6. Stress hyperglycemia: If HbA1c <6.5% with elevated hospital glucose, insulin may be temporary; arrange glucose monitoring at 1 month as 60% will develop diabetes within one year 1